Cemiplimab (Libtayo®): A Comprehensive Monograph on a PD-1 Checkpoint Inhibitor in Modern Oncology

Executive Summary

Cemiplimab, marketed under the brand name Libtayo®, is a fully human IgG4 monoclonal antibody that functions as a programmed death receptor-1 (PD-1) immune checkpoint inhibitor. By binding to the PD-1 receptor on T-cells, Cemiplimab blocks its interaction with ligands PD-L1 and PD-L2, thereby releasing the brakes on the immune system and restoring T-cell-mediated anti-tumor activity. This mechanism has demonstrated broad and durable efficacy across a range of malignancies.

Developed by Regeneron Pharmaceuticals, Inc., Cemiplimab has achieved landmark regulatory approvals from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). It was the first systemic therapy approved for advanced cutaneous squamous cell carcinoma (CSCC), establishing a new standard of care in a setting with a significant unmet need. Subsequent approvals were secured for advanced basal cell carcinoma (BCC) in patients who have progressed on or are intolerant to hedgehog pathway inhibitors, another niche population with limited options.

In the highly competitive landscape of non-small cell lung cancer (NSCLC), Cemiplimab is approved both as a monotherapy for first-line treatment of patients whose tumors exhibit high PD-L1 expression (Tumor Proportion Score ≥ 50%) and in combination with platinum-based chemotherapy for a broader first-line population without EGFR, ALK, or ROS1 aberrations. The pivotal EMPOWER-Lung 1 trial demonstrated a remarkable and durable overall survival benefit for Cemiplimab monotherapy over chemotherapy.

Furthermore, Cemiplimab is approved for the second-line treatment of recurrent or metastatic cervical cancer, where it has shown a significant survival advantage over chemotherapy irrespective of the patient's PD-L1 status. This particular finding underscores the indication-specific nature of biomarkers in immuno-oncology.

The safety profile of Cemiplimab is consistent with the PD-1 inhibitor class, characterized by a spectrum of immune-mediated adverse reactions (imARs) affecting various organ systems. These reactions, while potentially severe or fatal, are generally manageable with established protocols involving corticosteroids and vigilant monitoring.

Strategically, Cemiplimab represents the cornerstone of Regeneron's oncology franchise. Its journey from a co-development partnership with Sanofi to a wholly-owned Regeneron asset signifies the company's commitment to becoming a major independent player in the oncology market. Supported by a robust and expanding clinical development program, Cemiplimab is positioned not only as a critical therapeutic option for its approved indications but also as a foundational agent for future combination strategies in oncology.

I. Drug Profile and Pharmacological Characteristics

1.1. Identification and Molecular Structure

Cemiplimab is a protein-based, biotech therapeutic agent classified as a fully human immunoglobulin G4 (IgG4​) monoclonal antibody.[1] It is produced in Chinese Hamster Ovary (CHO) cell suspension cultures using recombinant DNA technology.[4] In the United States, the nonproprietary name is designated as cemiplimab-rwlc, with the "-rwlc" suffix assigned by the FDA in accordance with its guidance on naming biological products.[5] The drug is formulated as a sterile, clear to slightly opalescent, colorless to pale yellow solution for intravenous infusion.[4]

Table 1: Cemiplimab Drug Identifiers

Identifier	Value	Source(s)
Generic Name	Cemiplimab	8
US-Designated Name	Cemiplimab-rwlc	5
Brand Name	Libtayo®	1
DrugBank ID	DB14707	[User Query]
CAS Number	1801342-60-8	9
Drug Class	Antineoplastic Agent, Programmed Death Receptor-1 (PD-1) Antagonist/Inhibitor	9
Type	Biotech, Protein-Based Therapy, Monoclonal Antibody (mAb)	8
Isotype	Human IgG4	2
Molecular Formula	C6380​H9808​N1688​O2000​S44​	9
Synonyms	REGN2810, REGN-2810, SAR-439684	2
Developer/Manufacturer	Regeneron Pharmaceuticals, Inc.	5

1.2. Mechanism of Action: PD-1 Checkpoint Inhibition

The therapeutic activity of Cemiplimab is rooted in its function as an immune checkpoint inhibitor.[1] The programmed death-1 (PD-1) receptor is an inhibitory co-receptor expressed on the surface of activated T-cells, B-cells, and myeloid cells. Its primary role is to act as a negative regulator of T-cell function, maintaining peripheral tolerance and preventing excessive or harmful immune responses.[3] This regulation is mediated through the binding of PD-1 to its two known ligands: programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2), which are expressed on antigen-presenting cells and can be upregulated on the surface of various tumor cells.[8]

Many malignancies exploit this natural immune checkpoint to evade detection and destruction by the host immune system. By expressing PD-L1 and/or PD-L2, tumor cells can engage the PD-1 receptor on tumor-infiltrating T-cells, triggering downstream signaling cascades that inhibit T-cell proliferation, cytokine production (e.g., interferon-gamma), and cytotoxicity, effectively rendering the anti-tumor immune response inert.[3]

Cemiplimab is a high-affinity, potent, fully human monoclonal antibody that binds specifically to the PD-1 receptor.[2] This binding physically obstructs the interaction between PD-1 and both of its ligands, PD-L1 and PD-L2.[2] By preventing this ligand-receptor engagement, Cemiplimab removes the PD-1-mediated suppression of T-cell activity. This disinhibition, or "release of the brakes," restores and potentiates the T-cell-mediated immune response against cancer cells, leading to enhanced tumor cell killing.[8] Preclinical studies in syngeneic mouse tumor models confirmed that blocking PD-1 activity with Cemiplimab resulted in decreased tumor growth.[6]

The decision to target the PD-1 receptor itself, rather than one of its ligands, provides a more comprehensive blockade of this immune checkpoint axis. While clinical focus is often placed on PD-L1 expression as a biomarker, tumors may utilize either PD-L1 or PD-L2 for immune evasion. A therapy targeting only the PD-L1 ligand could potentially be circumvented by tumors that predominantly express PD-L2. By blocking the common receptor, Cemiplimab ensures that signaling through this pathway is inhibited regardless of which ligand is the primary driver of T-cell suppression in a given tumor microenvironment. This comprehensive blockade may contribute to Cemiplimab's broad efficacy across different cancer histologies and its effectiveness in indications where PD-L1 expression is not a prerequisite for treatment, such as cervical cancer.

1.3. Pharmacokinetics and Pharmacodynamics (PK/PD)

The pharmacokinetic profile of Cemiplimab has been characterized in clinical studies and supports its established dosing regimen.

• Absorption and Bioavailability: Cemiplimab is administered via intravenous infusion. Its pharmacokinetics are linear and dose-proportional over a dosage range of 1 mg/kg to 10 mg/kg every two weeks, as well as at the approved fixed dose of 350 mg every three weeks. Following this regimen, steady-state concentrations are typically achieved by approximately four months of treatment.[9]
• Distribution: As a large protein, Cemiplimab is primarily distributed within the vascular system, with a volume of distribution at steady state of approximately 5.2 L.[3] As a human IgG4 antibody, it is expected to be capable of crossing the placental barrier, which has important implications for its use during pregnancy.[3] It is not known if Cemiplimab is distributed into human milk.[9]
• Metabolism and Elimination: Like other therapeutic monoclonal antibodies, Cemiplimab is expected to be metabolized via proteolytic degradation into small peptides and individual amino acids, which are then recycled or eliminated.[9] It has a terminal half-life of approximately 19 to 19.4 days.[3] The clearance is approximately 0.21 L/day and is noted to be about 34% lower at steady state than after the initial dose, a phenomenon consistent with target-mediated drug disposition where binding to the PD-1 target influences drug clearance.[3]
• Special Populations: Clinical studies have shown that no dose adjustments are necessary based on age, gender, body weight, race, or cancer type. Furthermore, mild-to-moderate renal impairment (creatinine clearance [Clcr​] ≥25 mL/minute) or mild hepatic impairment (total bilirubin up to 2.63 mg/dL) does not have a clinically meaningful effect on the exposure of Cemiplimab.[9] The drug has not been studied in patients with severe hepatic or renal impairment.

The pharmacokinetic profile, particularly the long terminal half-life of approximately 19 days, is a key determinant of the drug's clinical utility. This extended half-life ensures that therapeutic concentrations are maintained well above the effective threshold throughout the approved 21-day (3-week) dosing interval. This alignment allows for a convenient, less frequent, fixed-dose regimen (350 mg every 3 weeks), which improves patient convenience, reduces the logistical burden on healthcare systems and infusion centers, and simplifies clinical practice compared to weight-based or more frequent dosing schedules.[7]

II. Clinical Development and Efficacy Analysis by Indication

The clinical development program for Cemiplimab, centered around the pivotal EMPOWER trial series, has successfully established its efficacy and secured approvals across four distinct cancer types. The program has strategically targeted areas of high unmet medical need, leading to practice-changing outcomes.

2.1. Cutaneous Squamous Cell Carcinoma (CSCC)

Cemiplimab's initial approval marked a watershed moment in the treatment of advanced cutaneous squamous cell carcinoma (CSCC), the second most common skin cancer.[17] Prior to its introduction, patients with metastatic (mCSCC) or locally advanced (laCSCC) disease who were not candidates for curative surgery or radiation had no approved systemic therapy options and faced a poor prognosis.[15]

The approval was based on the EMPOWER-CSCC-1 (Study 1540/1423) trial, a Phase I/II, open-label, multicenter study that enrolled patients with mCSCC or laCSCC.[17] This trial provided the largest prospective dataset in advanced CSCC to date and was the basis for the FDA granting Cemiplimab both Breakthrough Therapy and Priority Review designations, recognizing its potential for substantial improvement over available care.[1]

• Pivotal Efficacy Data: The primary endpoint was the objective response rate (ORR) as assessed by an independent central review (ICR). The initial combined analysis of 108 patients demonstrated a robust ORR of 47.2% (95% CI: 38, 57).[1] This efficacy was consistent across disease stages, with an ORR of 47% in the mCSCC cohort and 49% in the laCSCC cohort.[23] Crucially, these responses were highly durable, with 61% of responding patients having a duration of response (DOR) of 6 months or longer at the time of the analysis.[23]
• Long-Term Follow-Up and Fixed-Dose Confirmation: The durability of Cemiplimab's benefit was confirmed in a final, long-term analysis of the first three trial cohorts (n=193). After a median follow-up of 42.5 months, the ORR remained consistent at 47.2%. The estimated 12-month DOR was 88.3%, and the median progression-free survival (PFS) reached an impressive 26.0 months, underscoring the profound and lasting impact of the therapy.[24] Furthermore, a separate cohort (Group 6, n=165) treated with the now-standard 350 mg every 3 weeks fixed dose demonstrated a comparable ORR of 44.8%, validating the efficacy and convenience of this simplified regimen.[24]
• Real-World Evidence: The CASE study (NCT03836105), a Phase IV prospective study, has corroborated these findings in a real-world clinical setting. Interim results showed an ORR between 43.7% and 55.2% and a median PFS of 14.7 months. This confirmation is particularly significant as the CASE study included patients with poorer performance status (ECOG 2-3) who would have been ineligible for the pivotal EMPOWER-CSCC-1 trial, suggesting the drug's effectiveness translates to a broader patient population.[25]

By filling a complete therapeutic vacuum with a highly effective and durable agent, Cemiplimab not only became the definitive standard of care for advanced CSCC but also set a high efficacy bar for any future therapies entering this space. Ongoing investigations are now exploring its role in earlier disease stages, such as in the adjuvant setting for high-risk CSCC after surgery and radiation (NCT03969004), with the goal of preventing disease recurrence.[14]

2.2. Basal Cell Carcinoma (BCC)

Following its success in CSCC, Cemiplimab was developed for another challenging non-melanoma skin cancer population: patients with advanced basal cell carcinoma (BCC) who have progressed on or are intolerant to first-line therapy with a hedgehog pathway inhibitor (HHI).[5] This development program demonstrates a repeatable model for securing approvals by targeting well-defined, post-standard-of-care patient populations with high unmet needs.

The pivotal evidence comes from the EMPOWER-BCC 1 (NCT03132636) trial, a Phase II, open-label study that was the largest prospective trial conducted in this specific patient setting.[28]

• Efficacy in Locally Advanced BCC (laBCC): In the cohort of 84 patients with laBCC, Cemiplimab demonstrated clinically meaningful antitumor activity. The ORR, as assessed by ICR, was 31% (95% CI: 21-42), which included 6% of patients achieving a complete response (CR) and 25% achieving a partial response (PR).[29] The responses were durable, with a median PFS estimated at 19 months and an estimated 2-year overall survival (OS) rate of 80%.[29]
• Efficacy in Metastatic BCC (mBCC): In the cohort of 54 patients with mBCC, the confirmed ORR per ICR was 24.1%. The median DOR was 16.7 months, and the 12-month Kaplan-Meier estimated OS rate was 84.4%.[27] Based on these response rate and durability data, the mBCC indication was granted accelerated approval by the FDA, with continued approval contingent upon verification of clinical benefit in confirmatory trials.[8]

This strategic approach of identifying a patient population with limited options after failure of the established standard of care (HHIs) allowed for a focused, single-arm trial design. The positive results established Cemiplimab as the first immunotherapy to demonstrate a clinical benefit in this setting, mirroring the successful strategy employed in CSCC and providing a critical new treatment option for these patients.[27]

2.3. Non-Small Cell Lung Cancer (NSCLC)

Cemiplimab has entered the highly competitive first-line NSCLC market with two distinct approvals, positioning it as both a monotherapy for a biomarker-selected population and as a combination therapy for a broader group of patients.

2.3.1. Monotherapy in High PD-L1 Expressing NSCLC

The approval for Cemiplimab as a single agent is for the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have high PD-L1 expression (TPS ≥ 50%) and no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS proto-oncogene 1 (ROS1) aberrations.[31]

This approval was based on the EMPOWER-Lung 1 (NCT03088540) trial, a randomized, open-label, global Phase 3 study comparing Cemiplimab monotherapy (350 mg every 3 weeks) to investigator's choice of platinum-doublet chemotherapy.[32] A key feature of the trial design was that it permitted patients in the chemotherapy arm to cross over to receive Cemiplimab upon disease progression, with a high crossover rate of 74% ultimately observed.[33]

Despite the potential for this high crossover rate to dilute the survival difference between the arms, the trial demonstrated a profound and statistically significant benefit for initiating treatment with Cemiplimab. This finding strongly suggests that the timing of immunotherapy is critical, and the benefit of receiving it in the first-line setting is so substantial that it cannot be fully replicated by receiving it as a later-line therapy.

• Pivotal Efficacy (5-Year Follow-up, PD-L1 ≥50% cohort, n=565):
• Overall Survival (OS): Cemiplimab nearly doubled the median OS compared to chemotherapy, at 26.1 months versus 13.3 months (Hazard Ratio 0.59; 95% CI: 0.48-0.72).[35] The 5-year OS probability was 29.0% for the Cemiplimab arm versus 15.0% for the chemotherapy arm.[35]
• Progression-Free Survival (PFS): Median PFS was significantly improved at 8.1 months for Cemiplimab versus 5.3 months for chemotherapy (HR 0.50; 95% CI: 0.41-0.61).[35]
• Objective Response Rate (ORR): The ORR was more than doubled with Cemiplimab at 46.5%, compared to 20.6% for chemotherapy.[36]
• Biomarker Correlation: The trial confirmed a strong correlation between the level of PD-L1 expression and the magnitude of clinical benefit, with patients having the highest expression levels (≥90%) deriving the most significant improvements.[35]

2.3.2. Combination Therapy with Chemotherapy

Cemiplimab is also approved for first-line treatment in combination with platinum-based chemotherapy for adult patients with advanced or metastatic NSCLC with no EGFR, ALK, or ROS1 aberrations.[1] This approval was based on the

EMPOWER-Lung 3 trial. The U.S. approval for this combination is notably broad, applying to patients irrespective of their PD-L1 expression level, whereas the corresponding European approval is more restrictive, limited to patients with PD-L1 expression of ≥1%.[4] In the PD-L1 ≥1% population, the combination demonstrated a significant OS benefit, with a median OS of 22 months versus 13 months for chemotherapy alone.[38]

2.4. Cervical Cancer

Cemiplimab has also been approved for patients with recurrent or metastatic cervical cancer whose disease has progressed during or after treatment with platinum-based chemotherapy, addressing another area with limited effective options.[39]

The approval was based on the EMPOWER-Cervical 1 (NCT03257267) trial, a randomized, open-label, international Phase 3 study. The trial compared Cemiplimab monotherapy to investigator's choice of single-agent chemotherapy (e.g., pemetrexed, vinorelbine, gemcitabine, or topotecan).[41] The trial was stopped early in March 2021 based on a unanimous recommendation from the Independent Data Monitoring Committee due to a highly significant OS benefit observed with Cemiplimab.[39]

• Pivotal Efficacy (Final Analysis, 47.3-month follow-up):
• Overall Survival (OS): The final analysis confirmed a durable and statistically significant survival benefit. Median OS was 11.7 months for patients treated with Cemiplimab versus 8.5 months for those receiving chemotherapy (HR 0.67; 95% CI: 0.56-0.80; p <.00001).[41] This represents a 33% reduction in the risk of death.
• Efficacy by Histology and PD-L1 Status: A critical finding from this trial was that the survival benefit was maintained across different patient subgroups. The benefit was observed in patients with both squamous cell carcinoma and adenocarcinoma histologies.[42] Most importantly, the OS benefit was evident regardless of the patients' tumor PD-L1 expression status, including in those with PD-L1 <1%.[39]
• Quality of Life: Beyond survival, Cemiplimab also provided a superior patient experience. Patients treated with Cemiplimab reported statistically significant and clinically meaningful improvements in global health status/quality of life, physical functioning, role functioning, and key symptoms such as appetite loss and pain when compared to patients receiving chemotherapy.[44]

The PD-L1 agnostic efficacy observed in cervical cancer stands in stark contrast to the biomarker-driven indication for NSCLC monotherapy. This discrepancy highlights that the predictive value of PD-L1 expression is not universal across all cancers. The underlying biology of the tumor microenvironment—which in cervical cancer is often influenced by its viral etiology (Human Papillomavirus, HPV) and may involve different immune cell infiltrates or a greater reliance on the PD-L2/PD-1 axis—is a critical, indication-specific determinant of response to checkpoint inhibition. For clinicians, this simplifies the treatment algorithm for second-line cervical cancer, as PD-L1 testing is not required to select patients for Cemiplimab therapy.

2.5. Investigational Pipeline

Cemiplimab continues to be evaluated in a broad range of clinical trials, both as a monotherapy and as a backbone for combination therapies, exploring its utility in various cancers and treatment settings. Active recruiting trials include studies in:

• Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN): A Phase 3 trial is testing Cemiplimab plus surgery versus surgery alone.[46]
• Malignant Tumor of Colon: A Phase 1/2 trial is evaluating Cemiplimab in combination with SNS-101 (an anti-VISTA antibody).[47]
• Neoadjuvant/Intralesional Skin Cancers: Phase 1 and 2 trials are investigating Cemiplimab in the neoadjuvant (pre-surgical) setting for CSCC and BCC, as well as intralesional administration, to potentially shrink tumors and make them easier to remove.[10]
• Combination Lung Cancer Therapy: A Phase 1b study is evaluating the safety and efficacy of Cemiplimab in combination with Sarilumab (an IL-6 receptor antibody) for NSCLC.[49]

Additionally, a Phase 2 trial in metastatic cancer has been completed [50], while a Phase 1 combination study in NSCLC was terminated, reflecting the normal attrition process of clinical development.[51]

III. Safety and Tolerability Profile

As an immune checkpoint inhibitor, Cemiplimab's mechanism of action—enhancing the body's immune response—can lead to a unique spectrum of adverse reactions resulting from the immune system attacking normal organs and tissues. These immune-mediated adverse reactions (imARs) are a hallmark of the PD-1/PD-L1 inhibitor class. While these reactions can be severe or fatal, they are generally manageable with early identification and established treatment protocols.[1]

3.1. Overview of Common Adverse Reactions

The most frequently reported adverse reactions vary depending on whether Cemiplimab is used as a single agent or in combination with chemotherapy.

• As a Single Agent (Monotherapy): The most common adverse reactions, occurring in ≥15% of patients across clinical trials, include fatigue, musculoskeletal pain, rash, diarrhea, and anemia.[7]
• In Combination with Platinum-Based Chemotherapy: The most common adverse reactions (≥15%) include alopecia (hair loss), musculoskeletal pain, nausea, fatigue, peripheral neuropathy, and decreased appetite.[7]

3.2. In-Depth Analysis of Immune-Mediated Adverse Reactions (imARs)

The most clinically significant toxicities associated with Cemiplimab are imARs, which can manifest during treatment or even after discontinuation.[16] Vigilant monitoring for signs and symptoms is crucial for patient safety.

• Immune-Mediated Pneumonitis: Inflammation of the lungs occurred in 2.6% of 1281 patients treated with Cemiplimab, including Grade 3 (0.6%) and Grade 4 (0.3%) events. Pneumonitis led to permanent discontinuation of the drug in 1.3% of patients. The incidence is known to be higher in patients who have received prior thoracic radiation.[52]
• Immune-Mediated Colitis: Inflammation of the intestine, primarily presenting as diarrhea, occurred in 2.0% of patients, including Grade 3 (0.8%) events. It led to permanent discontinuation in 0.4% of patients. In cases of corticosteroid-refractory colitis, reactivation of cytomegalovirus (CMV) has been reported with PD-1/PD-L1 inhibitors.[52]
• Immune-Mediated Hepatitis: Liver inflammation occurred in 2.4% of patients, including fatal (<0.1%), Grade 4 (0.3%), and Grade 3 (1.6%) events. Hepatitis led to permanent discontinuation in 1.4% of patients. A subset of patients (13%) required additional immunosuppression with mycophenolate.[52]
• Immune-Mediated Endocrinopathies: Dysfunction of endocrine glands is a common imAR. This includes hypothyroidism (the most frequent, occurring in up to 10% of patients), hyperthyroidism, adrenal insufficiency, hypophysitis (inflammation of the pituitary gland), and immune-mediated type 1 diabetes mellitus, which can present with diabetic ketoacidosis.[1]
• Immune-Mediated Nephritis with Renal Dysfunction: Kidney inflammation occurred in 0.7% of patients, including fatal (<0.1%) and Grade 3 (<0.1%) events. It led to permanent discontinuation in 0.2% of patients.[52]
• Severe Dermatologic Reactions: While rash is common, severe and life-threatening skin reactions have been reported, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).[1]
• Other Immune-Mediated Reactions: A wide range of other imARs have been observed, though less frequently. These include myocarditis (inflammation of the heart muscle), pericarditis, encephalitis, Guillain-Barré syndrome, myasthenia gravis, vasculitis, and Sjogren's syndrome.[3]

3.3. Management of Adverse Reactions

The management of imARs is grade-dependent and follows a standardized algorithm. The cornerstone of treatment is the temporary withholding or permanent discontinuation of Cemiplimab and the administration of systemic corticosteroids.

For most Grade 2 imARs, Cemiplimab is withheld. For Grade 3 or 4 imARs, Cemiplimab is typically permanently discontinued. Systemic corticosteroid therapy, such as prednisone at a dose of 1 to 2 mg/kg/day or equivalent, should be initiated promptly. Once the adverse reaction improves to Grade 1 or less, a corticosteroid taper should be initiated and continued over at least one month.[9]

Table 2: Management of Key Immune-Mediated Adverse Reactions

Adverse Reaction	Severity (Grade)	Dosage Modification of Cemiplimab	Management
Pneumonitis	Grade 2	Withhold	Initiate corticosteroids; may resume Cemiplimab after taper if toxicity resolves to Grade 0-1.
	Grade 3 or 4	Permanently Discontinue	Initiate corticosteroids.
Colitis	Grade 2 or 3	Withhold	Initiate corticosteroids; may resume Cemiplimab after taper if toxicity resolves to Grade 0-1.
	Grade 4	Permanently Discontinue	Initiate corticosteroids.
Hepatitis	ALT/AST >3 to 8x ULN or Total Bilirubin >1.5 to 3x ULN	Withhold	Initiate corticosteroids; may resume Cemiplimab after taper if toxicity resolves to Grade 0-1.
	ALT/AST >8x ULN or Total Bilirubin >3x ULN	Permanently Discontinue	Initiate corticosteroids.
Endocrinopathies	Grade 2-4	Withhold if clinically necessary	Initiate corticosteroids for certain Grade ≥2 events; administer hormone replacement as needed.
Nephritis with Renal Dysfunction	Grade 2 or 3 increased creatinine	Withhold	Initiate corticosteroids; may resume Cemiplimab after taper if toxicity resolves.
	Grade 4 increased creatinine	Permanently Discontinue	Initiate corticosteroids.
Exfoliative Dermatologic Conditions	Suspected SJS, TEN, DRESS	Withhold	Initiate corticosteroids.
	Confirmed SJS, TEN, DRESS	Permanently Discontinue	Initiate corticosteroids.
Source: Synthesized from 4

3.4. Warnings, Precautions, and Contraindications

• Embryo-Fetal Toxicity: Cemiplimab can cause fetal harm. As an IgG4 antibody, it is expected to cross the placenta. Animal models have shown that blocking the PD-1/PD-L1 pathway can disrupt maternal immune tolerance to the fetus and increase the risk of fetal loss. Women of reproductive potential must be advised of this risk and should use effective contraception during treatment and for at least 4 months after the final dose.[1]
• Lactation: It is not known if Cemiplimab is secreted in human milk, but due to the potential for serious adverse reactions in the breastfed infant, breastfeeding should be discontinued during treatment and for at least 4 months after the final dose.[9]
• Allogeneic HSCT Complications: Patients who receive an allogeneic hematopoietic stem cell transplant (HSCT) before or after treatment with a PD-1 inhibitor are at increased risk for serious and fatal complications, including graft-versus-host disease (GVHD).[3]
• Infusion-Related Reactions: Reactions can occur during infusion. Depending on the severity (Grade 1-4), management may involve slowing the infusion rate, interrupting the infusion, or permanent discontinuation of therapy.[3]
• Contraindications: There are no known contraindications to the use of Cemiplimab listed in the provided prescribing information.[9]

IV. Regulatory and Commercial Landscape

The regulatory and commercial trajectory of Cemiplimab illustrates a highly successful strategy of targeting unmet needs, expanding indications based on robust clinical data, and adapting corporate structure to maximize asset value.

4.1. U.S. Food and Drug Administration (FDA) Approval Pathway

Cemiplimab's journey with the FDA has been marked by a series of rapid and impactful approvals, often facilitated by expedited review programs that recognized the drug's significant therapeutic advances.

• September 28, 2018 (Advanced CSCC): The initial approval made Cemiplimab the first-ever systemic therapy available for patients with metastatic or locally advanced CSCC who are not candidates for curative surgery or radiation. This landmark approval was preceded by the FDA granting it Breakthrough Therapy Designation in September 2017 and Priority Review in April 2018.[18]
• February 9, 2021 (Advanced BCC): The second major indication was approved for patients with locally advanced or metastatic BCC who had progressed on or were intolerant to HHI therapy. The approval was full for laBCC and accelerated for mBCC, and the application also received Priority Review.[12]
• February 22, 2021 (First-Line NSCLC Monotherapy): Cemiplimab was approved as a first-line monotherapy for patients with advanced NSCLC whose tumors have high PD-L1 expression (TPS ≥ 50%).[22]
• November 8, 2022 (First-Line NSCLC Combination Therapy): The label was expanded to include use in combination with platinum-based chemotherapy for first-line treatment of advanced NSCLC, importantly, irrespective of PD-L1 status.[1]

4.2. European Medicines Agency (EMA) Approval Pathway

The approval process in the European Union has largely paralleled that in the U.S., establishing Cemiplimab as a key therapeutic option across Europe.

• June 28, 2019 (Advanced CSCC): The EMA granted a conditional marketing authorization for advanced CSCC, recognizing the high unmet need. This was later converted to a full, standard marketing authorization on July 1, 2022, after the submission of additional supporting data.[21]
• June 25, 2021 (Advanced BCC & NSCLC Monotherapy): In a significant milestone, the European Commission (EC) approved Cemiplimab for two indications concurrently: for advanced BCC post-HHI therapy and for first-line NSCLC monotherapy in patients with PD-L1 ≥50%.[28]
• November 22, 2022 (Recurrent/Metastatic Cervical Cancer): Cemiplimab was approved as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after platinum-based chemotherapy.[39]
• NSCLC Combination Therapy: The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval for Cemiplimab in combination with chemotherapy for NSCLC patients with PD-L1 expression ≥1%, a more restrictive label than the corresponding U.S. approval.[38]

Table 3: Global Regulatory Milestones for Cemiplimab (Libtayo®)

Date	Regulatory Body	Action	Indication	Source(s)
Sep 2017	FDA	Breakthrough Therapy Designation	Advanced CSCC	22
Apr 2018	FDA	Priority Review Granted	Advanced CSCC	22
Sep 28, 2018	FDA	Approval	Advanced CSCC	22
Jun 28, 2019	EMA	Conditional Approval	Advanced CSCC	21
Feb 9, 2021	FDA	Approval (Full & Accelerated)	Advanced BCC (laBCC & mBCC)	12
Feb 22, 2021	FDA	Approval	1L NSCLC Monotherapy (PD-L1 ≥50%)	32
Jun 25, 2021	EMA	Approval	Advanced BCC & 1L NSCLC Monotherapy (PD-L1 ≥50%)	28
Jul 1, 2022	EMA	Full Authorization Granted	Advanced CSCC (Conversion from Conditional)	57
Nov 8, 2022	FDA	Approval	1L NSCLC Combination Therapy	5
Nov 22, 2022	EMA	Approval	2L Recurrent/Metastatic Cervical Cancer	39

4.3. Corporate Strategy and Market Positioning

Cemiplimab was invented using Regeneron's proprietary VelocImmune® technology, which is designed to produce optimized fully human antibodies.[5] It was initially developed and commercialized under a global collaboration agreement between Regeneron and Sanofi.[17]

A pivotal shift in corporate strategy occurred on July 1, 2022, when Regeneron acquired Sanofi's stake, gaining exclusive worldwide rights to develop, manufacture, and commercialize Cemiplimab.[5] This move was not merely a financial transaction but a profound strategic realignment. The initial partnership was a logical risk-sharing approach for Regeneron, a company historically known for its work in ophthalmology and inflammatory diseases rather than oncology. The decision to buy out Sanofi for a substantial sum signaled immense confidence in Cemiplimab's long-term value and marked Regeneron's evolution into a major, independent oncology player.

Regeneron leadership has explicitly stated that Libtayo is the "backbone of our oncology strategy".[5] This indicates that the company's future research and development in cancer will be heavily centered around combinations with Cemiplimab, leveraging it as a foundational immuno-oncology agent. To support this global strategy, Regeneron has entered into commercialization agreements with partners like Medison Pharma to ensure access and distribution in various international markets where it does not have its own commercial infrastructure.[58] This strategic bet on Cemiplimab has significant implications for Regeneron's R&D focus, commercial infrastructure build-out, and future revenue profile, firmly establishing its commitment to the oncology space.

V. Comparative Assessment and Future Directions

Situating Cemiplimab within the dynamic field of immuno-oncology requires a comparative look at its competitors, an understanding of the biomarkers that guide its use, and an analysis of its future developmental trajectory.

5.1. Positioning within the PD-1/PD-L1 Inhibitor Class

Cemiplimab entered an NSCLC market dominated by established PD-1/PD-L1 inhibitors such as Pembrolizumab (Keytruda) and Nivolumab (Opdivo). To gain market share in such a crowded field, a new agent must offer a compelling clinical advantage. While direct head-to-head randomized trials are lacking, network meta-analyses provide valuable cross-trial comparisons.

One such network meta-analysis of 13 randomized controlled studies in NSCLC provided intriguing evidence. The analysis confirmed that several PD-1/PD-L1 inhibitors, including Cemiplimab, significantly improved overall survival compared to chemotherapy. However, it further suggested that Cemiplimab was "numerically superior to other PD-1/PD-L1 agents" in terms of the OS hazard ratio.[59]

Critically, the analysis also assessed the balance between efficacy and safety. Using a Surface Under the Cumulative Ranking Curve (SUCRA) analysis, which integrates both benefit and risk, the study concluded that Cemiplimab "provided the most favorable balance between efficacy and safety," achieving the top ranking for overall survival.[59] This suggestion of a potentially superior risk-benefit profile is Cemiplimab's most critical potential differentiator in the competitive NSCLC landscape. For physicians, the possibility of achieving top-tier efficacy with a more favorable safety profile (fewer treatment-related adverse events) is a powerful consideration, especially for patients where managing toxicity is a primary concern. While this indirect evidence cannot replace a head-to-head trial, it provides a strong rationale for considering Cemiplimab and can influence clinical decision-making and treatment guidelines.

5.2. Role of Biomarkers in Patient Selection

The clinical development of Cemiplimab provides a masterclass in the nuanced and indication-specific application of biomarkers in oncology.

• Predictive Biomarker (PD-L1 in NSCLC): The approval for Cemiplimab monotherapy in first-line NSCLC is strictly limited to patients whose tumors have high PD-L1 expression (TPS ≥ 50%).[8] The data from the EMPOWER-Lung 1 trial clearly show a direct correlation between higher levels of PD-L1 expression and a greater magnitude of clinical benefit, cementing PD-L1 TPS as a critical predictive biomarker for patient selection in this context.[35]
• Biomarker Agnosticism (Cervical Cancer): In stark contrast, the approval and underlying efficacy data for second-line cervical cancer demonstrate a clear survival benefit for all patients, irrespective of their tumor's PD-L1 status.[39] This highlights that the immune contexture of the tumor microenvironment is a more powerful determinant of response than PD-L1 expression alone in certain diseases.
• Negative Selection Biomarkers (NSCLC): The NSCLC indications for Cemiplimab explicitly exclude patients with known EGFR, ALK, or ROS1 genomic aberrations.[1] These mutations are key negative selection biomarkers, as patients harboring them derive significantly more benefit from specific targeted therapies than from immunotherapy.

5.3. Future Research and Unmet Needs

The future of Cemiplimab's development is focused on expanding its utility through combination therapies and moving into earlier stages of disease.

• Combination Therapies: The future of immuno-oncology is widely seen to be in rational combinations. Cemiplimab is being actively investigated in combination with chemotherapy and other novel immunotherapies (e.g., anti-LAG-3, anti-VISTA) to overcome resistance and improve response rates.[6] The EMPOWER-Lung 1 trial itself explored an adaptive strategy of adding chemotherapy to Cemiplimab at the time of progression, which showed potential clinical benefit and may represent a new second-line treatment paradigm.[60]
• Earlier Lines of Therapy: A major strategic frontier for all checkpoint inhibitors is their use in earlier, potentially curative settings. Cemiplimab is being evaluated in the adjuvant setting (post-surgery) for high-risk CSCC to prevent recurrence.[26] Furthermore, neoadjuvant (pre-surgery) trials in both CSCC and BCC are assessing whether Cemiplimab can shrink tumors, improve surgical outcomes, and potentially lead to higher cure rates.[10] Success in these trials would dramatically expand the eligible patient population and shift the treatment paradigm towards earlier intervention.

VI. Concluding Analysis and Strategic Recommendations

6.1. Synthesis of Cemiplimab's Clinical Value and Market Impact

Cemiplimab has successfully carved out a significant position in the immuno-oncology armamentarium. Its clinical value is multifaceted, defined by its pioneering role in previously untreatable cancers and its competitive efficacy in more established indications.

• Strengths: Cemiplimab's primary strengths lie in its first-in-class approval for advanced CSCC and its role in filling a critical unmet need for post-HHI advanced BCC. It demonstrates robust and durable monotherapy efficacy in high PD-L1 NSCLC and unique PD-L1 agnostic efficacy in second-line cervical cancer. Its potentially favorable risk-benefit profile compared to competitors is a key asset.
• Weaknesses: As a later entrant into the vast but saturated NSCLC market, it faces significant competition from entrenched incumbents with longer track records and greater physician familiarity. The lack of direct head-to-head trial data against these competitors remains a challenge for market positioning.
• Opportunities: The greatest opportunities for Cemiplimab lie in its expansion into earlier, adjuvant and neoadjuvant treatment settings, which could substantially increase its patient base and clinical impact. It also has a major opportunity to serve as the foundational agent for Regeneron's proprietary combination therapy pipeline, securing its long-term relevance.
• Threats: The primary threat is the intense competition from other PD-1/PD-L1 inhibitors. Additionally, the rapid evolution of immuno-oncology means that novel checkpoint inhibitors targeting different pathways (e.g., LAG-3, TIGIT, VISTA) could emerge as superior partners in combination therapies, potentially challenging Cemiplimab's role as a backbone agent.

6.2. Recommendations for Clinical Practice

For practicing oncologists, the evidence supports the following clinical positioning for Cemiplimab:

• Advanced CSCC: Cemiplimab is the established standard of care for patients with metastatic or locally advanced disease who are not candidates for curative local therapies.
• Advanced BCC: It is a critical and approved second-line option for patients with locally advanced or metastatic disease who have progressed on or are intolerant to HHI therapy.
• First-Line Advanced NSCLC: Patient selection is paramount. For monotherapy, patients must have tumors with high PD-L1 expression (TPS ≥ 50%) and no actionable EGFR, ALK, or ROS1 mutations. For combination therapy with chemotherapy, it is a viable option for patients without these driver mutations, irrespective of PD-L1 status in the U.S.
• Second-Line Cervical Cancer: It is a new standard of care for patients with recurrent or metastatic disease who have progressed after platinum-based chemotherapy, and its use does not require prior PD-L1 testing.
• Safety Management: Across all indications, clinicians must maintain a high index of suspicion for the development of imARs and be prepared to implement established management protocols involving treatment interruption/discontinuation and corticosteroid administration.

6.3. Outlook for Future Development and Commercialization

Cemiplimab has firmly established itself as a versatile and valuable multi-indication immuno-oncology agent. Its future growth and long-term success will likely be determined by two primary factors. First, the outcomes of its ongoing trials in earlier-stage, adjuvant, and neoadjuvant settings will be critical; positive results in these studies would significantly expand its market and solidify its role in potentially curative treatment paradigms. Second, its ability to be successfully integrated as the backbone of Regeneron's future combination therapy strategies will define its enduring relevance in an immuno-oncology landscape that is rapidly moving beyond monotherapy. The strategic decision by Regeneron to take full ownership of the asset underscores a deep corporate commitment to realizing this potential.

Works cited

1. Cemiplimab - Wikipedia, accessed July 25, 2025, https://en.wikipedia.org/wiki/Cemiplimab
2. Cemiplimab (anti-PD-1) - Selleck Chemicals, accessed July 25, 2025, https://www.selleckchem.com/products/cemiplimab.html
3. DRUG NAME: Cemiplimab - BC Cancer, accessed July 25, 2025, http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Cemiplimab_monograph.pdf
4. Libtayo, INN-cemiplimab - EMA, accessed July 25, 2025, https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf
5. Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC) - Regeneron Investor Relations, accessed July 25, 2025, https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-rwlc-combination-chemotherapy-approved-fda/
6. Cemiplimab CAS#: 1801342-60-8 - ChemicalBook, accessed July 25, 2025, https://m.chemicalbook.com/ProductChemicalPropertiesCB68081098_EN.htm
7. LIBTAYO Full Prescribing Information - Regeneron, accessed July 25, 2025, https://www.regeneron.com/downloads/libtayo_fpi.pdf
8. Cemiplimab: Uses, Interactions, Mechanism of Action - DrugBank, accessed July 25, 2025, https://go.drugbank.com/drugs/DB14707
9. Cemiplimab-rwlc Monograph for Professionals - Drugs.com, accessed July 25, 2025, https://www.drugs.com/monograph/cemiplimab-rwlc.html
10. Cemiplimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery | ClinicalTrials.gov, accessed July 25, 2025, https://clinicaltrials.gov/study/NCT05929664
11. Regeneron Pharmaceuticals - Cemiplimab - AdisInsight - Springer, accessed July 25, 2025, https://adisinsight.springer.com/drugs/800042079
12. FDA approves cemiplimab-rwlc for locally advanced and metastatic basal cell carcinoma, accessed July 25, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-locally-advanced-and-metastatic-basal-cell-carcinoma
13. Cemiplimab-rwlc - NCI, accessed July 25, 2025, https://www.cancer.gov/about-cancer/treatment/drugs/cemiplimab-rwlc
14. Advanced Cutaneous Squamous Cell Carcinoma Management in Immunotherapy Era: Achievements and New Challenges - PMC, accessed July 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10656166/
15. Libtayo (Cemiplimab-rwlc), a PD-1 Inhibitor, First Drug Approved by the FDA for Patients with Advanced Cutaneous Squamous-Cell Carcinoma - The Oncology Pharmacist, accessed July 25, 2025, https://www.theoncologypharmacist.com/2019-fourth-annual-oncology-guide-to-new-fda-approvals/libtayo-cemiplimab-rwlc-a-pd-1-inhibitor-first-drug-approved-by-the-fda-for-patients-with-advanced-cutaneous-squamous-cell-carcinoma
16. LIBTAYO (cemiplimab-rwlc) Label - accessdata.fda.gov, accessed July 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761097s001lbl.pdf
17. FDA Approves Libtayo® (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma | Regeneron Pharmaceuticals Inc., accessed July 25, 2025, https://investor.regeneron.com/news-releases/news-release-details/fda-approves-libtayor-cemiplimab-rwlc-first-and-only-treatment/
18. fda approves libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma - Florida Society of Clinical Oncology, accessed July 25, 2025, https://flasco.org/fda-approves-libtayo-cemiplimab-rwlc-as-first-and-only-treatment-for-advanced-cutaneous-squamous-cell-carcinoma/
19. Libtayo (Cemiplimab-rwlc), a PD-1 Inhibitor, First Drug Approved by the FDA for Patients with Advanced Cutaneous Squamous-Cell Carcinoma - Journal of Oncology Navigation & Survivorship, accessed July 25, 2025, https://jons-online.com/special-issues-and-supplements/2019/2019-fourth-annual-oncology-guide-to-new-fda-approvals/libtayo-cemiplimab-rwlc-a-pd-1-inhibitor-first-drug-approved-by-the-fda-for-patients-with-advanced-cutaneous-squamous-cell-carcinoma
20. Regeneron and Sanofi Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma, accessed July 25, 2025, https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-positive-topline-pivotal-results/
21. Libtayo® (cemiplimab) Approved for Advanced Cutaneous Squamous Cell Carcinoma in the European Union - PR Newswire, accessed July 25, 2025, https://www.prnewswire.com/news-releases/libtayo-cemiplimab-approved-for-advanced-cutaneous-squamous-cell-carcinoma-in-the-european-union-300878561.html
22. Libtayo (cemiplimab-rwlc) FDA Approval History - Drugs.com, accessed July 25, 2025, https://www.drugs.com/history/libtayo.html
23. FDA approves cemiplimab-rwlc for metastatic or locally advanced cutaneous squamous cell carcinoma, accessed July 25, 2025, https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-cemiplimab-rwlc-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma
24. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6 - Research Profiles at Washington University School of Medicine, accessed July 25, 2025, https://profiles.wustl.edu/en/publications/a-phase-2-open-label-study-of-cemiplimab-in-patients-with-advance
25. CemiplimAb-rwlc survivorship and epidemiology (CASE): Interim results from a prospective study of the safety and effectiveness of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting. - ASCO Publications, accessed July 25, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.9533
26. Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | ClinicalTrials.gov, accessed July 25, 2025, https://clinicaltrials.gov/study/NCT03969004
27. Cemiplimab for Metastatic Basal Cell Carcinoma: Exploring the Data With Karl Lewis, MD, accessed July 25, 2025, https://oncdata.com/cemiplimab-for-metastatic-basal-cell-carcinoma-exploring-the-data-with-karl-lewis-md/
28. Press Release: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma - Sanofi, accessed July 25, 2025, https://www.sanofi.com/en/media-room/press-releases/2021/2021-06-25-05-15-26-2252997
29. Cemiplimab Shows Clinical Benefit for BCC After Hedgehog Inhibitor Therapy, accessed July 25, 2025, https://www.cancernetwork.com/view/cemiplimab-shows-clinical-benefit-for-bcc-after-hedgehog-inhibitor-therapy
30. Cemiplimab in locally advanced basal cell carcinoma after ..., accessed July 25, 2025, https://pubmed.ncbi.nlm.nih.gov/34000246/
31. LIBTAYO® (cemiplimab-rwlc) injection, for ... - accessdata.fda.gov, accessed July 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761097s014lbl.pdf
32. FDA approves cemiplimab-rwlc for non-small cell lung cancer with ..., accessed July 25, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-non-small-cell-lung-cancer-high-pd-l1-expression
33. Phase 3 EMPOWER-Lung 1 Study of Cemiplimab in Advanced PD-L1–Positive NSCLC, accessed July 25, 2025, https://jhoponline.com/lung-cancer/18448-phase-3-empower-lung-1-study-of-cemiplimab-in-advanced-pd-l1-positive-nsclc
34. Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression, accessed July 25, 2025, https://www.sanofi.com/en/media-room/press-releases/2021/2021-06-25-05-00-00-2252992
35. Cemiplimab Monotherapy for First-Line Treatment of Patients with ..., accessed July 25, 2025, https://pubmed.ncbi.nlm.nih.gov/40118215/
36. EMPOWER-Lung 1: First-Line Cemiplimab Shows 'Durable Clinical Benefits' in NSCLC, accessed July 25, 2025, https://www.lungcancerstoday.com/post/empower-lung-1-first-line-cemiplimab-shows-durable-clinical-benefits-in-nsclc
37. New Paper Alert: EMPOWER-Lung 1 Trial: Cemiplimab Shows 5-Year Survival Benefit in Advanced NSCLC with High PD-L1 Expression - Oncodaily, accessed July 25, 2025, https://oncodaily.com/oncolibrary/empower-lung1-cemiplimab-for-ansclc
38. Libtayo secures EMA committee backing for first-line lung cancer - FirstWord Pharma, accessed July 25, 2025, https://firstwordpharma.com/story/5709430
39. Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology, accessed July 25, 2025, https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-approved-european-commission-first-0/
40. EMA Recommends Extension of Indications for Cemiplimab, accessed July 25, 2025, https://www.esmo.org/oncology-news/ema-recommends-extension-of-indications-for-cemiplimab2
41. Cemiplimab in recurrent cervical cancer: Final analysis of overall ..., accessed July 25, 2025, https://pubmed.ncbi.nlm.nih.gov/39798514/
42. ESMO Congress 2022: results of two VHIO-led studies evidence the promise of immunotherapy in advanced cervical cancer, accessed July 25, 2025, https://vhio.net/2022/09/10/esmo-congress-2022-results-of-two-vhio-led-studies-evidence-the-promise-of-immunotherapy-in-advanced-cervical-cancer/
43. Long-Term Follow-Up Confirms Survival Benefit from Second-Line Cemiplimab for Recurrent/Metastatic Cervical Cancer - Targeted Oncology, accessed July 25, 2025, https://www.targetedonc.com/view/long-term-follow-up-confirms-survival-benefit-from-second-line-cemiplimab-for-recurrent-metastatic-cervical-cancer
44. EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer - ResearchGate, accessed July 25, 2025, https://www.researchgate.net/publication/362376467_EMPOWER_CERVICAL-1_Effects_of_cemiplimab_versus_chemotherapy_on_patient-reported_quality_of_life_functioning_and_symptoms_among_women_with_recurrent_cervical_cancer
45. Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer - PubMed, accessed July 25, 2025, https://pubmed.ncbi.nlm.nih.gov/35922251/
46. Recurrent Squamous Cell Carcinoma of the Head and Neck Recruiting Phase 3 Trials for Cemiplimab (DB14707) - DrugBank, accessed July 25, 2025, https://go.drugbank.com/indications/DBCOND0142919/clinical_trials/DB14707?phase=3&status=recruiting
47. Malignant Tumor of Colon Recruiting Phase 1 / 2 Trials for Cemiplimab (DB14707), accessed July 25, 2025, https://go.drugbank.com/indications/DBCOND0053164/clinical_trials/DB14707?phase=1%2C2&status=recruiting
48. Cutaneous Squamous Cell Carcinoma Recruiting Phase 1 Trials for Cemiplimab (DB14707), accessed July 25, 2025, https://go.drugbank.com/indications/DBCOND0055244/clinical_trials/DB14707?phase=1&status=recruiting
49. Cemiplimab Recruiting Phase 1 Trials for Lung Cancer Treatment | DrugBank Online, accessed July 25, 2025, https://go.drugbank.com/drugs/DB14707/clinical_trials?conditions=DBCOND0028388&phase=1&purpose=treatment&status=recruiting
50. Metastatic Cancer Completed Phase 2 Trials for Cemiplimab (DB14707) | DrugBank Online, accessed July 25, 2025, https://go.drugbank.com/indications/DBCOND0028461/clinical_trials/DB14707?phase=2&status=completed
51. NSCLC (Non-small Cell Lung Carcinoma) Terminated Phase 1 Trials for Cemiplimab (DB14707) - DrugBank, accessed July 25, 2025, https://go.drugbank.com/indications/DBCOND0103105/clinical_trials/DB14707?phase=1&status=terminated
52. LIBTAYO® (cemiplimab-rwlc): Official Healthcare Professional Website, accessed July 25, 2025, https://www.libtayohcp.com/
53. Cemiplimab (Libtayo®) as monotherapy for the treatment of recurrent or metastatic cervical cancer, accessed July 25, 2025, https://eprints.aihta.at/1413/1/Fact%20Sheet%20Nr.113_Update.pdf
54. Libtayo (cemiplimab) dosing, indications, interactions, adverse effects, and more, accessed July 25, 2025, https://reference.medscape.com/drug/libtayo-cemiplimab-1000263
55. Libtayo Medication Guide - Regeneron, accessed July 25, 2025, https://www.regeneron.com/downloads/libtayo-medication-guide.pdf
56. FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma - Sanofi, accessed July 25, 2025, https://www.sanofi.com/en/media-room/press-releases/2021/2021-02-09-22-15-00-2172711
57. Libtayo | European Medicines Agency (EMA), accessed July 25, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo
58. Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries - PR Newswire, accessed July 25, 2025, https://www.prnewswire.com/il/news-releases/medison-pharma-announces--agreement-with-regeneron-pharmaceuticals-to-commercialize-libtayo-cemiplimab-in-multiple-countries-302028356.html
59. Comparative Efficacy and Safety of Anti-PD-1/PD-L1 for the ..., accessed July 25, 2025, https://pubmed.ncbi.nlm.nih.gov/35619899/
60. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial - PubMed, accessed July 25, 2025, https://pubmed.ncbi.nlm.nih.gov/37591293/